Crohn's Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year (CHARGE)
Research type
Research Study
Full title
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
IRAS ID
1013251
Contact name
David Wright
Contact email
Sponsor organisation
Janssen-Cilag International N.V.
Eudract number
2025-521590-13
ISRCTN Number
ISRCTN39379437
Research summary
Crohn’s disease (CD) is a long-term, progressive (worsens with time) and life-threatening disease of the digestive system. Inflammation due to the disease penetrates the lining of digestive tract and may cause ulcers to form. Although guselkumab and risankizumab are approved treatments, still more information is needed to understand which treatment works better for patients with moderately to severely active CD who did not respond to other treatments.
Guselkumab and risankizumab are monoclonal antibodies* that blocks interleukin 23 (IL-23)**.
Blocking the effects of IL-23 helps to reduce the inflammation that occurs in CD.
*A type of protein designed to recognise and attach to a specific target.
**A specific type of protein involved in inflammation.
In this study, researchers want to assess how well guselkumab works compared to risankizumab in patients with moderately to severely active CD.REC name
Wales REC 1
REC reference
26/WA/0033
Date of REC Opinion
17 Mar 2026
REC opinion
Further Information Favourable Opinion